Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Regulatory News (AGL)

Share Price Information for Angle (AGL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 18.75
Bid: 18.00
Ask: 19.50
Change: 0.25 (1.35%)
Spread: 1.50 (8.333%)
Open: 18.50
High: 19.50
Low: 17.75
Prev. Close: 18.50
AGL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Contract Win

27 Nov 2009 07:00

RNS Number : 1665D
Angle PLC
27 November 2009
 



For immediate release

27 November 2009

ANGLE plc ("the Company")

Contract Win

ANGLE plc ("ANGLE"), the international venture management company focusing on the commercialisation of technology and innovation, is delighted to announce a new contract win for its Management Services business worth £2.3 million over three years.

The contract, which was the subject of a competitive tendering process, is to deliver Innovation Advice and Guidance in Lincolnshire, a product in the UK Government's Solutions for Business portfolio, on behalf of Lincolnshire County Council. The contract follows ANGLE's successful delivery oa previous programme, Innovation Lincolnshire, since May 2007. 

 

The programme brings the techniques and benefits of innovation to small businesses, identifying openings for innovation based business improvement. These include stimulating growth through the introduction of new products and services and delivering operational improvement through innovative business process change.  ANGLE's specialist consultants provide complete SME innovation support service, from innovation opportunity identification, training, business analysis and support to project implementation.

Innovation is considered by Lincolnshire's public sector partners to be crucial to the county's development and prosperityDeveloped as part of the Lincolnshire Economic Strategy, the Programme is part of the county's  contribution to the East Midlands Regional Innovation Strategy.

Commenting on the award of this new contract, Programme Director Dr Shane Booth said: 

"We are delighted to have been given the opportunity to continue working with delivery partners and businesses across Lincolnshire. Our success in securing this contract reflects the methodologies, delivery processes, expertise and management we have developed to drive innovation. In the earlier programme, we deployed these to assist projects as diverse as the development of new musical instruments, designing special packaging to redeploy a bulk product for retail sale and the creation of a new, mobile biomass heating system."

ANGLE Founder and Chief Executive, Andrew Newland, added:

"This contract confirms the attraction of our capabilities and approach to public sector organisations seeking to deploy technology and innovation as tools for business growth and consequent regional economic development. Our strategy of focusing on long term contracts in cases where we can add substantial value continues to be highly successful for ANGLE. We look forward to the potential of rolling out these capabilities throughout the UK and beyond."

 

For further information:

ANGLE plc

01483 685830

Andrew Newland, Chief Executive

Ian Griffiths, Finance Director

Collins Stewart Europe Limited

Stewart Wallace

0207 523 8350

Scott Harris 

Stephen Scott, James O'Shaughnessy, Harry Dee

0207 653 0030

Notes to Editors

ANGLE plc 

Founded in 1994, ANGLE is an international venture management company focusing on the commercialisation of technology and the development of technology-based industry. ANGLE creates, develops and advises technology businesses on its own behalf and for its clients.

ANGLE's specialist Management services business provides support on a fee-for-service basis to major clients around the world involved in incubation, IP commercialisation, SME innovation and growth and the operation of science & technology parks.

ANGLE also owns a portfolio of companies with high growth potential in the medical and technology sectors in both the UK and the US. These have been developed whilst subsidiaries of ANGLE using its proprietary Progeny® process. ANGLE seeks to retain a substantial shareholding in these companies with a view to ongoing returns from dividend, milestone, royalty and capital returns.

ANGLE's venture management and technology commercialisation skills are of increasing relevance as global economies focus on regeneration, innovation and value added components to their industries. ANGLE's technology skills in IT and software, medical and life sciences, clean tech and renewable energies are directly relevant to major growth markets of the future and are marketed as specialised Management services.

ANGLE is quoted on AIM (AGL.L); further information can be found on www.ANGLEplc.com 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
CNTUNRNRKORAUAA
Date   Source Headline
6th Jul 201710:05 amRNSNotice of Results
4th Jul 20177:00 amRNSSuccessful Headline Data in Ovarian Cancer Studies
15th Jun 20177:00 amRNSParsortix breakthrough in prostate cancer
5th Jun 20177:00 amRNSSuccess with Parsortix in Colorectal Cancer
3rd May 20177:00 amRNSBusiness Update
4th Apr 20177:00 amRNSHolding(s) in Company
3rd Apr 20177:00 amRNSParsortix enables analysis in head and neck cancer
30th Mar 20177:00 amRNSProstate Cancer Update
14th Feb 201711:39 amEQSEdison issues outlook on Angle
13th Feb 20177:00 amRNSSelected for European Cancer ID Programme
26th Jan 20177:01 amRNSInterim Evaluation of Ovarian Cancer Study
26th Jan 20177:00 amRNSInterim Results
4th Jan 20177:00 amRNSNotice of Results
28th Nov 20167:00 amRNSISSUE OF SHARE OPTIONS
24th Nov 20162:48 pmRNSResult of GM
4th Nov 20167:00 amRNSBarts Research Supports Potential Use of Parsortix
1st Nov 20167:00 amRNSNotice of GM
27th Oct 20167:00 amRNSDirector's share purchase
7th Oct 201611:57 amRNSHolding(s) in Company
4th Oct 20164:35 pmRNSResult of AGM
30th Sep 20167:00 amRNSResearch published in Clinical Chemistry
19th Sep 201611:14 amRNSIssue of Equity
9th Sep 20164:12 pmRNSAnnual Report and Accounts and Notice of AGM
4th Aug 20167:00 amRNSMD Anderson Cancer Center poster presentation
2nd Aug 20163:37 pmRNSEdison issues ADR update on Angle
28th Jul 20167:00 amRNSUse of Parsortix in GANNET53 drug trial
28th Jul 20167:00 amRNSPreliminary Results
27th Jul 20167:00 amRNSInitiation of 200 patient US ovarian cancer study
19th Jul 20167:00 amRNSInitiation of European ovarian cancer study
15th Jul 20167:00 amRNSNotice of Results
15th Jul 20167:00 amRNSParsortix gaining traction at EACR Conference
1st Jun 20163:04 pmRNSHolding(s) in Company
31st May 20164:36 pmRNSHolding(s) in Company
27th May 20163:12 pmRNSEdison issues research update on Angle
25th May 20167:00 amRNSCancer Research UK Contract
25th May 20167:00 amRNSPlacing
29th Apr 20167:00 amRNSNEW PUBLICATIONS UTILISING PARSORTIX
19th Apr 201612:43 pmRNSEdison issues research update on Angle
18th Apr 20167:00 amRNSParsortix potential in metastatic breast cancer
21st Mar 201612:12 pmRNSEdison issues research update on Angle
21st Mar 20167:00 amRNSParsortix potential for prostate cancer detection
9th Mar 20167:00 amRNSEuropean patent grant for Parsortix
28th Jan 20167:00 amRNSInterim Results
27th Jan 201610:42 amRNSNotice of Interim Results
25th Jan 20167:00 amRNSUKE publishes evaluation of Parsortix
22nd Dec 20157:00 amRNSCompletion of Geomerics Transaction
15th Dec 20157:00 amRNSParsortix first commercial sales
10th Dec 20157:00 amRNSChange of FTSE Industry Classification Benchmark
30th Nov 20155:56 pmRNSHolding(s) in Company
17th Nov 20157:00 amRNSLung Cancer Research Publication

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.